Growth Hormone Deficiency in Mild Traumatic Brain Injury
Growth Hormone Treatment, Growth Hormone Deficiency, Concussion, Mild
About this trial
This is an interventional treatment trial for Growth Hormone Treatment focused on measuring Growth Hormone Deficiency, Persistent Post-concussion Symptoms, Growth Hormone Therapy, Clinical Trial
Eligibility Criteria
Inclusion Criteria: Sustained a concussion according to the American Congress of Rehabilitation Medicine criteria with persistent symptoms 6-months following concussion Peak growth hormone of < 3 mcg/L following glucagon stimulation test Exclusion Criteria: Untreated pituitary dysfunction Moderate/severe TBI Intracranial abnormalities Chronic neurologic conditions
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Growth Hormone
Placebo
Participants will perform daily at-home subcutaneous GH injections after receiving thorough at-home education training provided by a pharmaceutical nurse before and research personnel. The GH will be provided be Pfizer. Starting doses will be 0.2 ug/L and 0.3 ug/L for women taking exogenous oral estrogen.
Participants will perform daily at-home subcutaneous placebo injections after receiving thorough at-home education training provided by a pharmaceutical nurse before and research personnel. Starting doses will be 0.2 ug/L and 0.3 ug/L for women taking exogenous oral estrogen.